

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

**Roxadustat for treating anaemia in people with chronic kidney disease
ID1483**

Provisional stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Astellas Pharma Ltd (roxadustat) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Kidney Care UK • Kidney Research UK • Muslim Council of Britain • National Kidney Federation • Polycystic Kidney Disease Charity • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Anaemia Nurse Specialist Association • Association of Renal Technologists • British Association of Urological Nurses • British Association of Urological Surgeons • British Committee for Standards in Haematology • British Geriatrics Society • British Renal Society • British Society for Haematology • British Society for Human Genetics • Renal Association • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for DGH Nephrologists • The Urology Foundation • UK Clinical Pharmacy Association • UK Forum on Haemoglobin Disorders 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutic and Toxicology Centre • Allied Health Professionals Federation • Association of Renal Industries • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee • Welsh Kidney Patients Association <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Accord (ferrous sulfate) • Amgen (darbepoetin alfa) • Pfizer (epoetin zeta) • Janssen (epoetin alfa) • Pharmacosmos (iron dextran, iron (III) isomaltoside 1000) • Sun Pharma (ferrous sulfate) • Roche (epoetin beta, methoxy polyethylene glycol-epoetin beta) • Sandoz (ferrous sulfate) • Vifor Pharma (iron sucrose) • Wallace (ferrous sulfate)

Appendix C

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • UK National Screening Committee • UK Renal Pharmacy Group • United Kingdom Primary Immunodeficiency Network <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • NHS Islington CCG • NHS Liverpool CCG • Welsh Government 	<ul style="list-style-type: none"> • Wockhardt (ferrous sulfate) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Kidney and Transplant Group • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

¹ Non company consultees are invited to submit statements relevant to the group they are representing.